About: Establishment and development of national community-based collaborative innovation demonstration areas to achieve the control target of hepatitis B in China

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Establishment and development of national community-based collaborative innovation demonstration areas to achieve the control target of hepatitis B in China Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Establishment and development of national community-based collaborative innovation demonstration areas to achieve the control target of hepatitis B in China
Creator	Wu, Nanping Xie, Tiansheng Pang, Xinghuo Chen, Ping Li, Qing Lu, Lin Zhou, Hong Jiang, Wei Zhu, Fengcai Hou, Yunde Li, Mengfeng Tang, Hong Li, Lanjuan Sheng, Jifang Yang, Shigui Li, Dexin Wu, Zunyou Zhou, Lin Deng, Min Li, Yiping Ren, Jingjing Ruan, Bing Wang, Chencheng Xu, Kaijin Hao, Yuantao Yuan, Zhengan Jin, Shuigao Xu, Aiqiang Gu, Jinhui Yao, Jun Chen, Yude Gao, Di Hu, Jianping Li, Guojian Li, Zizhao Meng, Qun Ni, Mingjian Wu, Peixin Xing, Ruoqi Yan, Yongping Yang, Wen Yu, Chengbo Yu, Zhixin Zhang, Guangyu Zhao, Yanhong Zhong, Qiu
Source	PMC
abstract	BACKGROUND: The major infectious diseases of hepatitis B has constituted an acute public health challenge in China. An effective and affordable HBV control model is urgently needed. A national project of Community-based Collaborative Innovation HBV (CCI-HBV) demonstration areas has optimized the existing community healthcare resources and obtained initial results in HBV control. METHODS: Based on the existing community healthcare network, CCI-HBV project combined the community health management and health contract signing service for long-staying residents in hepatitis B screening. Moreover, HBV field research strategy was popularized in CCI-HBV areas. After screening, patients with seropositive results were enrolled in corresponding cohorts and received treatment at an early stage. And the uninfected people received medical supports including health education through new media, behavior intervention and HBV vaccinations. In this process, a cloud-based National Information Platform (NIP) was established to collect and store residents’ epidemiological data. In addition, a special quality control team was set up for CCI project. RESULTS: After two rounds of screening, HBsAg positive rate dropped from 5.05% (with 5,173,003 people screened) to 4.57% (with 3,819,675 people screened), while the rate of new HBV infections was 0.28 per 100 person-years in the fixed cohorts of 2,584,322 people. The quality control team completed PPS sampling simultaneously and established the serum sample database with 2,800,000 serum samples for unified testing. CONCLUSIONS: CCI-HBV project has established a large-scale field research to conduct whole-population screening and intervention. We analyzed the HBsAg prevalence and new infection rate of HBV in the fixed population for the epidemic trend and intervention effect. The purpose of CCI-HBV project is to establish and evaluate a practical model of grid management and field strategy, to realize the new goal to control hepatitis B in China. To provide policymakers with a feasible model, our results are directly applicable. TRIAL REGISTRATION: The project was funded by the Major Projects of Science Research for the 11th and 12th five-year plans of China, entitled “The prevention and control of AIDS, viral hepatitis and other major infectious diseases”, Grant Nos. 2009ZX10004901, 2011ZX10004901, 2013ZX10004904, 2014ZX10004007 and 2014ZX10004008.
has issue date	2019-07-12(xsd:dateTime)
bibo:doi	10.1186/s12879-019-4150-9
bibo:pmid	31299910
has license	cc-by
sha1sum (hex)	266638c157eeaa50a5be5c734ed71240faeafe93
schema:url	https://doi.org/10.1186/s12879-019-4150-9
resource representing a document's title	Establishment and development of national community-based collaborative innovation demonstration areas to achieve the control target of hepatitis B in China
has PubMed Central identifier	PMC6626343
has PubMed identifier	31299910
schema:publication	BMC Infect Dis
resource representing a document's body	covid:266638c157eeaa50a5be5c734ed71240faeafe93#body_text
is schema:about of	named entity 'Innovation' named entity 'HBV' named entity 'stage' named entity 'combined' named entity 'effective' named entity 'The major' named entity 'COHORTS' named entity 'CHALLENGE' named entity 'BEHAVIOR' named entity 'PROCESS' named entity 'TO COLLECT' named entity 'SPECIAL' named entity 'LONG' named entity 'QUALITY CONTROL' named entity 'residents' named entity 'healthcare' named entity 'community health' named entity 'seropositive' named entity 'hepatitis B' named entity 'control' named entity 'areas' named entity 'seropositive' named entity 'HBV' named entity 'quality control' named entity 'health education' named entity 'epidemiological data' named entity 'cloud-based' named entity 'HBV' named entity 'hepatitis' named entity 'EHRs' named entity 'data sources' named entity 'HBV' named entity 'China' named entity 'research based' named entity 'infection' named entity 'Public Account'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software